Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Clinical study

Drug interactions with immunomodulating drugs

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

The risk of immunomodulator-related drug interactions appears to be greatest with monoclonal antibodies (mAbs) that neutralise the effects of interleukin (IL)-6 in diseases with systemic inflammation, say authors of a systematic review published in BJCP (British Journal of Clinical Pharmacology). …
Literatur
Zurück zum Zitat de Jong LM, et al. A Systematic Review on Disease-Drug-Drug Interactions with immunomodulating drugs: A Critical Appraisal of Risk Assessment and Drug Labelling British Journal of Clinical Pharmacology : 28 Apr 2022. Available from: URL: http://doi.org/10.1111/bcp.15372 de Jong LM, et al. A Systematic Review on Disease-Drug-Drug Interactions with immunomodulating drugs: A Critical Appraisal of Risk Assessment and Drug Labelling British Journal of Clinical Pharmacology : 28 Apr 2022. Available from: URL: http://​doi.​org/​10.​1111/​bcp.​15372
Metadaten
Titel
Drug interactions with immunomodulating drugs
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-14898-2

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Cefepime